INOVIQ Ltd Annual Report 2022

IHC study of 144 tissue samples that demonstrated SubB2M staining score was significantly greater in malignant and metastatic samples when compared to benign (p < 0.003 and p < 0.03, respectively). Cells staining positive for SubB2M approached 100% in malignant and metastatic tissues. The ability of SubB2M IHC to correctly classify melanoma tissue samples was further assessed by Receiver Operating Characteristic Curve (ROC) analysis using a logistic regression model with 10-fold cross validation. The area under the ROC was 0.79, with the SubB2M IHC test correctly classifying 91% of malignant and metastatic melanoma tissue samples. Previous proof-of-concept studies by Griffith University showed compelling preliminary results for detection of breast and ovarian cancers with over 95% sensitivity and 100% specificity across all stages on a surface plasmon resonance (SPR) platform. Post year-end, on 29 July 2022, INOVIQ advised it had expanded its feasibility program for a highly sensitive SubB2M-based SPR11 test with a Canadianbased medtech company. The new SPR instrument allows for high throughput sample processing that could be performed in a central laboratory to detect Neu5Gc concentrations in a general health panel. Increased Neu5Gc concentrations in the blood may provide an early warning that an individual requires follow-up investigation for the presence of certain types of cancer such as breast, ovarian, prostate, pancreatic, kidney and melanoma.12 EXO-NET program EXO-NET is an immunoaffinity magnetic-bead capture technology that uses a proprietary multiantibody matrix coated on nanobeads to isolate exosomes based on their surface markers. The DNA, RNA, protein and lipid biomolecules found in exosomes have important applications in the research, diagnosis and treatment of cancer, inflammatory, metabolic, and neurodegenerative diseases. EXONET can be customized to capture specific types of EVs and can be fully-automated for high-throughput sample analysis for large scale clinical trials or routine pathology or CLIA laboratory applications. INOVIQ’s goal is to develop a portfolio of EXO-NET capture tools and EXO-NET powered exosome-based diagnostics for detection of cancer and other diseases. INOVIQ is engaging with key opinion leaders focused on exosome research to establish research collaborations for the development of more accurate and reliable exosome-based diagnostics. The Company expects to advance new EXONET collaborations with key opinion leaders for exosomebased capture tools and diagnostics for other cancers and diseases over the next 12-months. During the year, INOVIQ completed extensive in-house studies to develop a robust data package evidencing the utility of its EXO-NET Research Use Only (RUO) panexosome capture tool and its advantages over competitor products. Amanuscript is being prepared for publication 11 SPR = Surface Plasmon Resonance 12 Internal Griffith University SPR and INOVIQ IHC data 15 Annual Report 2022

RkJQdWJsaXNoZXIy MjE2NDg3